Key TakeawaysPatients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study.Zepbound patients lost an average 20% of their body weight compared with roughly 14% for those on Wegovy.Both weight-loss drug makers' stocks have slipped in recent months, but they remain in positive territory for the year. Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the ...